Traditional Chinese Herbal Formula Reverses Ovarian Aging via Nrf2 Antioxidant Pathway
Erzhi Tiangui formula restored estrous cycles, reduced ovarian follicle loss, and improved mitochondrial function in aged female mice.
Summary
Ovarian aging — marked by declining egg quality, follicle loss, and hormonal changes — is a major driver of female reproductive decline and broader aging. Researchers tested Erzhi Tiangui Formula (EZTG), a traditional Chinese herbal compound, in aged mice to see if it could slow this process. After just 10 days of treatment, aged mice showed restored estrous cycles, reduced follicle loss, and lower oxidative stress in ovarian granulosa cells. The formula activated the Nrf2/HO-1 antioxidant pathway, boosting protective enzymes (SOD, CAT, GPX1), reducing cell death signals, and improving mitochondrial energy production. Effects were dose-dependent, with medium and high doses outperforming low doses. Lab studies using human granulosa cells confirmed the Nrf2 pathway is essential for these benefits. The findings suggest EZTG may offer a natural, mechanism-based approach to addressing ovarian aging.
Detailed Summary
Ovarian aging is a defining feature of female reproductive senescence, characterized by a progressive decline in follicle quality and quantity, rising oxidative stress, and mitochondrial dysfunction in granulosa cells. Understanding and intervening in this process has implications not just for fertility, but for broader female healthspan, as ovarian function is linked to bone density, cardiovascular health, and cognitive aging.
This study examined whether Erzhi Tiangui Formula (EZTG), a compound derived from traditional Chinese medicine, could attenuate age-related ovarian decline. Researchers used 100 female C57BL/6J mice split into young controls (6–8 weeks) and aged groups (8–9 months). Aged mice received low, medium, or high doses of EZTG for 10 days, after which ovarian morphology, follicle counts, oxidative stress markers, antioxidant enzyme activity, apoptosis factors, and mitochondrial parameters were assessed. In vitro validation used human KGN granulosa cells under hydrogen peroxide-induced oxidative stress, with Nrf2 knockdown via siRNA to confirm pathway specificity.
EZTG produced significant, dose-dependent improvements across all measured outcomes. Treated aged mice showed restored estrous cyclicity and reduced follicular atresia. At the molecular level, the formula decreased reactive oxygen species (ROS) accumulation and activated the Nrf2/HO-1 signaling pathway — increasing Nrf2 and HO-1 expression while suppressing Keap1. Antioxidant enzymes SOD, CAT, and GPX1 were upregulated. Anti-apoptotic protein Bcl-2 rose while pro-apoptotic markers Bax and cleaved Caspase-3 fell. Mitochondrial membrane potential and ATP production also improved.
The in vitro siRNA knockdown experiments confirmed that Nrf2 is mechanistically required for EZTG's protective effects, not merely correlated with them.
Despite these promising results, this remains a preclinical mouse study. The short 10-day treatment window and absence of human clinical data limit translation. The formula's complex multi-herb composition also makes it difficult to attribute effects to specific active constituents, and summary data are based on the abstract only.
Key Findings
- EZTG restored estrous cyclicity and reduced follicular atresia in aged female mice after 10 days.
- The formula activated Nrf2/HO-1 signaling, upregulating antioxidant enzymes SOD, CAT, and GPX1 dose-dependently.
- Mitochondrial membrane potential and ATP production in granulosa cells were significantly improved by EZTG.
- Anti-apoptotic Bcl-2 increased while pro-apoptotic Bax and cleaved Caspase-3 decreased in treated mice.
- siRNA knockdown confirmed Nrf2 is mechanistically necessary for EZTG's protective effects in human granulosa cells.
Methodology
100 female C57BL/6J mice (young controls and aged groups) were treated with three doses of EZTG for 10 days, followed by gonadotropin stimulation to assess follicular response. Ovarian morphology, oxidative stress markers, apoptosis factors, and mitochondrial function were evaluated. In vitro validation used H₂O₂-stressed human KGN granulosa cells with and without EZTG-containing serum, and Nrf2 siRNA knockdown to confirm pathway specificity.
Study Limitations
This is a short-term (10-day) preclinical mouse study with no human clinical data, limiting direct translation to women's health practice. The complex multi-herb composition of EZTG makes it difficult to isolate the specific bioactive compounds responsible for observed effects. The summary is based on the abstract only, as the full text was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: